Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2021-03-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于终止公司2020年度非公开发行股票事项并撤回申请材料的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 瑞康医药集团股份有限公司 regarding the termination of its 2020 non-public issuance of A shares and the withdrawal of the related application materials. It details board and supervisory committee meetings, independent director opinions, and the rationale behind the termination decision. The document does not contain financial statements or detailed financial data but rather communicates a corporate action related to capital raising activities. This fits the definition of a Capital/Financing Update (CAP), as it updates on the company's financing activities, specifically the termination of a planned share issuance and withdrawal of application to the securities regulator. The document length is 2469 characters, which is relatively short but contains substantive information about the financing decision, not merely an announcement of a report publication or a regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2021-03-30 Chinese
2020年年度报告
Annual Report Classification · 100% confidence The document is titled "瑞康医药集团股份有限公司 2020 年年度报告全文" which translates to "Realcan Pharmaceutical Group Co., Ltd. 2020 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data for the year 2020, management discussion and analysis, business overview, financial performance, risk disclosures, and governance information. The document references the fiscal period as January 1, 2020 to December 31, 2020, and includes audited financial figures, management statements, and comprehensive business analysis. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. There is no indication that this is merely a report publication announcement or a certification letter. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-03-30 Chinese
独立董事述职报告（武滨）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2020 Annual Report" and is a detailed narrative by an independent director about their duties, attendance, opinions, investigations, committee work, and efforts to protect investor rights during the year 2020. It is a formal report of the director's activities and opinions rather than a financial report or regulatory filing. It does not contain financial statements or audit results, nor is it an announcement or proxy solicitation. The content aligns with a management or board-related report focusing on governance and director duties. Therefore, the best fitting category is Board/Management Information (MANG). The document length is 2145 characters, which is consistent with a detailed director report rather than a full annual report or audit report.
2021-03-30 Chinese
2020年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2020年度监事会工作报告' which translates to '2020 Supervisory Board Work Report' of 瑞康医药集团股份有限公司. It details the supervisory board's activities, oversight of company operations, financial condition, internal controls, and compliance with laws and regulations for the year 2020. It includes references to meetings, financial audits, internal control evaluations, and supervisory duties. The document is a report from the supervisory board summarizing their work and findings for the year, which is a type of management or oversight report rather than a full annual report or audit report. It is not an announcement or a brief notice but a substantive report on supervisory activities. This fits best under the category of Management Reports (MDA), which covers management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports. The document length (2706 characters) is sufficient for a detailed report but not a full annual report. Therefore, the classification is MDA with high confidence.
2021-03-30 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2020年度内部控制的自我评价报告" which translates to "2020 Annual Internal Control Self-Evaluation Report." It is a detailed report discussing the company's internal control system, governance, financial management, risk management, audit, and compliance with regulatory requirements. The document includes a statement from the board of directors, detailed descriptions of internal control principles, organizational structure, implementation, supervision, and identified issues with corrective plans. It is a comprehensive self-assessment report on internal controls for the fiscal year 2020. This type of document aligns with an Audit Report / Information (AR) category, as it focuses on internal control evaluation and audit-related information rather than a full annual report or other categories. The document length (8132 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-03-30 Chinese
2020年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled '鉴证报告' which translates to 'Assurance Report' or 'Audit Report'. It includes detailed financial data such as assets, liabilities, equity, and notes, signed by certified public accountants (CPAs) from an accounting firm. The presence of CPA signatures and detailed financial statement data indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2020
2021-03-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.